Marshall Wace North America’s Seres Therapeutics MCRB Stock Holding History

Marshall Wace North America’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$598K	Buy	+4,288	New	+$839K	﹤0.01%	1073
2021 Q2	–	Sell	-2,081	Closed	-$857K	–	1638
2021 Q1	$857K	Buy	+2,081	New	+$958K	﹤0.01%	1082
2019 Q3	–	Sell	-48,647	Closed	-$3.13M	–	1440
2019 Q2	$3.13M	Buy	48,647 +48,572	+64,763%	+$4.61M	0.02%	460
2019 Q1	$10K	Buy	+75	New	+$9.14K	﹤0.01%	1452

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace North America's MCRB Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Seres Therapeutics (MCRB) in Q3 2021: 4,288 shares worth $598K. The stake represents ﹤0.01% of the portfolio and ranks #1073 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in MCRB as recently as Q1 2021.

Marshall Wace North America first reported a position in MCRB in Q1 2019 and has held it in 4 quarters since. The position peaked at $3.13M in Q2 2019. 133 funds tracked by Wall St. Rank hold MCRB as of Q3 2021.

Marshall Wace North America held 4,288 shares of Seres Therapeutics worth $598K as of Q3 2021.
Seres Therapeutics was a new Marshall Wace North America position in Q3 2021.
Seres Therapeutics made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1073 holding.
Marshall Wace North America first reported a position in Seres Therapeutics in Q1 2019 and has held it in 4 quarters since.
Marshall Wace North America's Seres Therapeutics position peaked at $3.13M in Q2 2019.
133 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.